The Technical Analyst
BridgeBio Pharma Inc [BBIO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BridgeBio Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.12% $24.95
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 602.08 mill |
| EPS: | -3.95 |
| P/E: | -6.32 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 184.45 mill |
| Avg Daily Volume: | 1.701 mill |
| RATING 2024-04-18 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.32 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.08x |
| Company: PE -6.32 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-9.02 (-136.15%) $-33.97 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 23.41 - 26.49 ( +/- 6.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-12 | Kumar Neil | Buy | 313 588 | Restricted Stock Units |
| 2024-03-12 | Kumar Neil | Buy | 45 140 | Stock Option (right to buy) |
| 2024-03-12 | Stephenson Brian C | Buy | 107 278 | Restricted Stock Units |
| 2024-03-12 | Stephenson Brian C | Buy | 15 442 | Stock Option (right to buy) |
| 2024-03-01 | Scott Randal W. | Sell | 2 500 | Common Stock |
| INSIDER POWER |
|---|
| -18.27 |
| Last 100 transactions |
| Buy: 1 673 575 | Sell: 2 657 073 |
Forecast:
16:00 - $24.98
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $24.98
Forecast 2: 16:00 - $24.98
Forecast 3: 16:00 - $24.98
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $24.95 (-0.12% ) |
| Volume | 1.623 mill |
| Avg. Vol. | 1.701 mill |
| % of Avg. Vol | 95.40 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BBIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $33.19 | N/A | Active |
|---|
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Latest Press Releases
2024-04-10 07:30:00 - Press Release
Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Palo alto, calif., april 10, 2024 (globe newswire) -- bridgebio pharma, inc. (nasdaq: bbio) (“bridgebio” or the “company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on april 5, 2024, the compensation committee of bridgebio's board of directors approved equity grants to 19 new employees in restricted stock units for an aggregate of 93,088 shares of the company's common stock. one-fourth of the shares underlying each employee's restricted stock units will vest on may 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the company or one of its subsidiaries on such vesting dates...
2024-04-07 13:15:00 - Press Release
Bridgebio Pharma Presents Cardiac Magnetic Resonance (cmr) Imaging Evidence Consistent With Clinical Improvement Observed In The Attribute-cm Phase 3 Study In Patients With Transthyretin Amyloid Cardiomyopathy (attr-cm)
- in this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression
2024-03-20 07:30:00 - Press Release
Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Palo alto, calif., march 20, 2024 (globe newswire) -- bridgebio pharma, inc. (nasdaq: bbio) (“bridgebio” or the “company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on march 16, 2024, the compensation committee of bridgebio's board of directors approved equity grants to 16 new employees in restricted stock units for an aggregate of 71,146 shares of the company's common stock, with the effective date of march 18, 2024. one-fourth of the shares underlying each employee's restricted stock units will vest on february 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the company or one of its subsidiaries on such vesting dates...
2024-03-05 23:53:00 - Press Release
Bridgebio Pharma Announces Pricing Of Public Offering Of Common Stock
Palo alto, calif., march 05, 2024 (globe newswire) -- bridgebio pharma, inc. (nasdaq: bbio) (“bridgebio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on march 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions. in addition, bridgebio has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares of its common stock on the same terms and conditions. the gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $250...
2024-03-04 16:17:00 - Press Release
Bridgebio Pharma Announces Proposed Public Offering Of Common Stock
Palo alto, calif., march 04, 2024 (globe newswire) -- bridgebio pharma, inc. (nasdaq: bbio) (“bridgebio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common stock. bridgebio also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. all of the shares in the proposed offering are to be sold by bridgebio.
Latest News
2024-03-04 02:33:50 - Reuters
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.
2024-03-04 02:30:01 - Investors Business Daily
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. BridgeBio stock is nearing a breakout.
2024-02-22 09:41:03 - Zacks Investment Research
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.87 per share a year ago.
2024-02-15 11:06:43 - Zacks Investment Research
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-01-29 12:35:14 - InvestorPlace
3 Groundbreaking Biotech Stocks to Invest in Now
Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company before it releases positive results. But on the flip side, a single negative press release could send a stock tumbling with biotech stocks being so volatile.
2024-01-11 17:19:01 - Seeking Alpha
BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
BridgeBio Pharma, Inc. expects results from the phase 1/2 study, using gene therapy BBP-631 for the treatment of patients with congenital adrenal hyperplasia, in early 2024. The congenital adrenal hyperplasia treatment market is expected to reach $892 million by 2033. Potential FDA acceptance of regulatory application of acromidis for the treatment of patients with ATTR-CM, expected within 60 days after submission achieved December 5th of 2023.
2024-01-08 03:18:45 - Seeking Alpha
BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
BridgeBio's FDA filing for acoramidis and advances in KRAS mutation cancer treatment contrast with growing financial losses. Acoramidis competes with Pfizer's ATTR-CM treatments; BBIO's oncology focus includes promising KRAS inhibitors and RAS-targeting strategies. Financially, the Company reports increased net loss and share count, yet possesses a solid short-term solvency with high long-term debts.
2024-01-03 06:45:00 - The Motley Fool
2 Biotechs That Could Get Bought Out in 2024
With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumored to be receiving takeover interest from larger peers.
2023-12-18 05:34:00 - InvestorPlace
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.
2023-11-09 07:30:00 - GlobeNewsWire
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM will be presented at the AHA Scientific Sessions 2023, taking place in Philadelphia, Pennsylvania on November 11 - 13, 2023. As previously announced, a highly statistically significant result was observed on the primary endpoint of ATTRibute-CM with a Win Ratio of 1.8 (p